165.04 USD
↗ 8.39 (5.36%)AT CLOSE (03:59 PM EST)
Alnylam Pharmaceuticals, Inc.
ALNYNASDAQ • USD
165.35
↗ 0.31 (0.19%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
165.35
↗ 0.31 (0.19%)
Market: CLOSED
Alnylam Pharmaceuticals, Inc. (ALNY) trades at $165.04 per share. There is a divergence between signals — underlying fundamentals rate "Buy" but technical indicators lean "Strong Sell". This is driven by a robust Altman Z-Score, exceptional Return on Equity (75.6%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, ALNY trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Nov 13, 2026.
Open?$159.17
High?$168.35
Low?$158.83
Prev. Close?$156.65
Volume?3.6M
Avg. Volume?2.6M
VWAP?$165.20
Rel. Volume?1.38x
Bid / Ask
Bid?$164.80 × 80
Ask?$165.91 × 40
Spread?$1.11
Midpoint?$165.36
Valuation & Ratios
Market Cap?22.1B
Shares Out?133.9M
Float?133.6M
Float %?99.9%
P/E Ratio?8.11
P/B Ratio?6.13
EPS?$20.34
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Themes
Employees
2.5K
Market Cap
21.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2004-05-28
Address
675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?60
Z-Score?89
Momentum?60
Short Sent.?85
Piotroski F-Score?5/9Mixed
Altman Z-Score?3.78Safe
Confidence?77%Moderate
Short InterestLow
Short % of Float?4.09%Low
Short Interest?5.5M
Days to Cover?1.9
Free Float133.6M
Avg Daily Volume2.9M
Settlement Date2026-10-30
Financial Health
Current Ratio?2.48Strong
Quick Ratio?2.43Strong
Cash Ratio?0.85Adequate
Debt/Equity?0.28Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?8.1CHEAP▾
Peers100
S&P97
P/B?6.13FAIR▾
Peers100
S&P30
P/S?4.41FAIR▾
Peers100
S&P34
P/FCF?29.4FAIR▾
Peers100
S&P30
EV/EBITDA?20.7HIGH▾
Peers100
S&P23
EV/Sales?4.26FAIR▾
Peers100
S&P43
Returns & Efficiency
ROE?75.6%STRONG▾
Peers50
S&P95
ROA?34.1%STRONG▾
Peers50
S&P97
Cash Flow & Enterprise
FCF?$752.1M
Enterprise Value?$21.4B
Fundamentals ratios updated end of day